- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03772015
The Change in Vaginal Axis on MRI After Uterus Preserving Laparoscopic Lateral Mesh Suspension
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Hamidiye Sisli Etfal Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female genital prolapse
Exclusion Criteria:
- Patients who had pouch of Douglas obliteration
- Patients with enterocele
- Patients who have any congenital or acquired anatomic and reproductive anomaly
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study
Patients who had the operation of "laparoscopic lateral mesh suspension" for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month
|
MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
|
Control
Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
|
MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal axis
Time Frame: at 6th months after the operation
|
From the images obtained in the sagittal plane, the vagina, which will be observed as a high signal intensity linear structure in T2A images, and the levator plate extending as a flow-signal intensity flat structure in T1A images, will be evaluated. The angles between the pubococcygeal line and lower vaginal segment (angle A), between the levator plate and the pubococcygeal (angle B) and between lower and upper vaginal segments (angle C) will be measured. |
at 6th months after the operation
|
Vaginal distances
Time Frame: at 6th months after the operation
|
The distance between the posterior vaginal fornix and the midpoint of the anterior side of the 2nd vertebra will be measured in the mid-sagittal plane (PF-S2).
The distance between the right spina ischiadica and right vaginal fornix (RSI-RF), and, the distance between the left spina ischiadica and left vaginal fornix (LSI-LF) will be measured on T2A images acquired in the axial plane.
|
at 6th months after the operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urge Symptoms
Time Frame: Evaluation at postoperative 6th month
|
Michigan Incontinence Severity Index (M-ISI) scale will be used to assess subjective outcome including urge symptoms.
This scale has ten items, consisting of a total M-ISI domain (the sum of items 1-8) and a distinct Bother domain (the sum of items 9 and 10).
The total M-ISI score consists of three subdomains (items 1-3 for stress urinary incontinence [SUI], items 4-6 for urge urinary incontinence [UUI], and items 7 and 8 for Pad usage [PU].
The responses for each item range from 0 to 4 on a Likert-type scale, with higher values representing greater symptoms and greater bother.
Total domain and subdomain scores are obtained by simply adding the respective answers.
The minimally important difference has been determined for the following domains/subdomains: total M-ISI (4 points), SUI (2 points), UUI (2 points), and PU (1 point).
|
Evaluation at postoperative 6th month
|
Prolapse symptoms
Time Frame: Evaluation at postoperative 6th month
|
The POP-SS consists of seven items, each with a 5-point Likert response set (0 = never, 1 = occasionally, 2 = sometimes, 3 = most of the time and 4 = all of the time).
A total score (range 0-28) is calculated by summing the seven individual symptom responses to derive the POP-SS score.
In addition, women indicate which one of the seven symptoms causes them most bother.
|
Evaluation at postoperative 6th month
|
Sexual functions
Time Frame: Evaluation at postoperative 6th month
|
The FSFI evaluates sexual functioning in women and comprises of 19 questions with different answer choice scales referring the sexual life in the previous 4 weeks.
The answer choices in the FSFI carry a number of points and are summed to obtain six domain scores and an overall score.
For the latter, there is a threshold at 26.55 which means tFhat all values below are classed as indicating female sexual dysfunction (FSD).
The domain scores are obtained as the sum of points attributed to questions in that domain multiplied by the domain factor.
|
Evaluation at postoperative 6th month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ozan Dogan, MD, Hamidiye Sisli Etfal Training and Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 240918
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anatomical Pathological Condition
-
Assistance Publique - Hôpitaux de ParisAgence Regionale de Sante d'Ile de FranceCompletedAnatomical Pathological ConditionFrance
-
Abant Izzet Baysal UniversityRecruitingEducational Problems | Anatomical Pathological ConditionTurkey
-
Centre Hospitalier Universitaire de NiceCompletedUnrecognized Condition
-
Institute of Head and Neck Studies and Education...Completed
-
Hospital Universitario Virgen de la ArrixacaRecruitingCutaneous Melanoma | Anatomical Pathological ConditionSpain
-
Bispebjerg HospitalNot yet recruitingSarcopenia | Treatment Adherence and Compliance | Hospital Acquired Condition | Inactivity, PhysicalDenmark
-
Maastricht University Medical CenterCompletedFocus: Anabolic Response to Food Intake in Young Individuals | Condition Relevance: Skeletal Muscle Health, Sarcopenia
-
Albert Einstein College of MedicineCompletedPrecancerous Conditions | Leukoplakia | Erythroplasia | Oral PapillomasUnited States
-
Insel Gruppe AG, University Hospital BernUniversity of BernCompletedDelirium | Sarcopenia | Fall | Mobility Limitation | Hospital Acquired Condition | Immobility SyndromeSwitzerland
-
Vanderbilt UniversityUniversity of California, IrvineCompletedCondition 1 - Educational Condition (Educational Book Group) | Condition 2 - Non-educational Condition (Non-educational Book Group) | Condition 3 - Control Condition (No-book Group)United States
Clinical Trials on Magnetic resonance imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System NeoplasmUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States